NAN JU

Dr. NAN JU

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Bone
Verified
Journal Article
Open access
TKTakuya Kurihara
Takuya Kurihara
MSMunehisa Shimamura
Munehisa Shimamura
YEYuki Etani
Yuki Etani
TNTakaaki Noguchi
Takaaki Noguchi
YFYuji Fukuda
Yuji Fukuda
KEKosuke Ebina
Kosuke Ebina
Estrogen deficiency following menopause increases receptor activator of nuclear factor-kappa B ligand (RANKL) expression in osteoblasts, thereby promoting osteoclast differentiation, and enhances T cell-derived tumor necrosis factor-alpha (TNFα) production, which induces sclerostin expression in osteocytes, thereby inhibiting bone formation. This study aimed to develop a novel uncoupling therapeutic agent for osteoporosis. We developed microglial healing peptide 1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN), a modified RANKL peptide with N-terminal acetylation and C-terminal amidation lacking the osteoclast activating CD loop. Given the structural similarities of RANK and TNF receptor 1 (TNFR1), we hypothesized that MHP1-AcN could inhibit both the RANKL-RANK and TNFα-TNFR1 pathways to address the pathophysiology of osteoporosis, as evaluated in vitro and in vivo using an ovariectomized mouse model. In ovariectomized mice, MHP1-AcN inhibited osteoclastogenesis, reduced osteocytic sclerostin expression, prevented bone loss, and improved the femoral cancellous and cortical bone microarchitecture. Unlike anti-RANKL antibody, MHP1-AcN considerably preserved bone formation by osteoblasts and enhanced bone strength, as evidenced by increases in energy absorption capacity. In vitro, MHP1-AcN bound to both RANK and TNFR1, suppressing osteoclast activity via the RANKL-RANK pathway and reducing sclerostin expression through the TNFα-TNFR1-nuclear factor-kappa B pathway. MHP1-AcN did not affect osteoblast proliferation and differentiation or RANKL expression. MHP1-AcN effectively inhibits osteoclastogenesis and sclerostin-mediated suppression of bone formation while considerably preserving osteoblast function. These findings suggest that MHP1-AcN, which targets dual pathways critical for bone homeostasis, is a promising uncoupling therapeutic agent for osteoporosis.

9 July 2025 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YFYuji Fukuda
Yuji Fukuda
MSMunehisa Shimamura
Munehisa Shimamura
YEYuki Etani
Yuki Etani
TNTakaaki Noguchi
Takaaki Noguchi
TKTakuya Kurihara
Takuya Kurihara
KEKosuke Ebina
Kosuke Ebina
Osteoarthritis (OA) is a degenerative disease characterized by subchondral bone sclerosis, chronic inflammation, and cartilage degradation. Abnormal mechanical stress by meniscal deviation activates osteoclasts and induces the release of transforming growth factor-beta (TGF-β), which promotes mesenchymal stem cell (MSC)-mediated type H angiogenesis and osteogenesis, contributing to bone sclerosis and cartilage damage. Subsequently, macrophages recognize cartilage-derived damage-associated molecular patterns (DAMPs) via Toll-like receptor 4 (TLR4), polarizing into the pro-inflammatory M1 phenotype, thereby exacerbating synovitis and cartilage loss. We developed Microglia Healing Peptide 1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN), a modified peptide derived from receptor activator of nuclear factor-kappa B ligand (RANKL), exhibiting both anti-osteoclastic and anti-inflammatory properties. This study aimed to evaluate the therapeutic potential of MHP1-AcN in a murine OA model and elucidate its underlying mechanisms. OA was induced in mice via destabilization of the medial meniscus (DMM) surgery. Mice were randomly assigned to three groups (n = 8/group): Sham (sham surgery + saline), Vehicle (DMM + saline), and MHP1-AcN (DMM + MHP1-AcN). MHP1-AcN (600 µg) was administered intraperitoneally five times per week from a day after surgery. Knee joints were harvested at 2, 4, and 8 weeks post-surgery. In vitro, the effects of MHP1-AcN were assessed on osteoclast differentiation, inflammatory cytokine expression, and M1/M2 macrophage polarization using mouse bone marrow-derived macrophages. Additionally, its effects on TGF-β-induced osteogenic differentiation of bone marrow-derived MSCs (BMMSCs) and angiogenesis of human umbilical vein endothelial cells (HUVECs) were evaluated. MHP1-AcN markedly suppressed key pathological features of OA in vivo, including synovial inflammation, osteoclast-driven subchondral bone remodeling, aberrant angiogenesis, and cartilage degeneration. In vitro, MHP1-AcN effectively inhibited TLR4-mediated inflammatory cascades by reducing M1 macrophage polarization and inflammasome activation. Despite being derived from RANKL, MHP1-AcN supressed RANKL-induced osteoclastogenesis through NF-κB pathway suppression. Furthermore, MHP1-AcN attenuated TGF-β-induced osteogenic and angiogenic activities via Smad2 signaling inhibition in BMMSCs and HUVECs. MHP1-AcN attenuates OA progression by modulating multi-pathways including aberrant bone remodeling, angiogenesis, and macrophage polarization, representing a promising disease-modifying therapeutic candidate for OA.

1 December 2021 in Brain Research
Verified
Journal Article
Open access
KWKouji Wakayama
Kouji Wakayama
MSMunehisa Shimamura
Munehisa Shimamura
SYShota Yoshida
Shota Yoshida
HHHiroki Hayashi
Hiroki Hayashi
NJNAN JU
NAN JU
RMRyuichi Morishita
Ryuichi Morishita
Introduction: As several clinical trials have revealed that angiotensin-converting enzyme inhibitors and angiotensin II (Ang II) receptor blockers may be efficient in treating vascular dementia (VaD), the long-acting blockade of the renin-angiotensin system (RAS) would be useful considering the poor adherence of antihypertensive drugs. Accordingly, we continuously blocked RAS via vaccination and examined the effectiveness of the VaD model in rats. Methods: Male Wistar rats were exposed to two-vessel occlusions (2VO) after three injections of Ang II peptide vaccine. The effects of the vaccine were evaluated in the novel object recognition test, brain RAS components, and markers for oligodendrocytes. Results: In the vaccinated rats, anti-Ang II antibody titer level was increased in serum until Day 168, but not in cerebral parenchyma. Vaccinated rats showed better object recognition memory with inhibited demyelination in the corpus callosum and activation of astrocytes and microglia. Also, levels of BrdU/GST pi-positive cells and the phosphorylation of cAMP response element binding protein was increased in vaccinated rats, indicating that the differentiation of oligodendrocyte progenitor cells to mature oligodendrocytes was accelerated. Vaccinated rats showed increased expression of fibroblast growth factor-2 (FGF2), which was observed in endothelial cells. Angiotensinogen mRNA was decreased at 7 days after 2VO but increased at 14 and 28 days. Conclusion: Ang II vaccine might have promoted oligodendrocyte differentiation and inhibited astrocytic and microglial activation by stimulating FGF2 signaling in the endothelial cells-oligodendrocyte/astrocyte/microglia coupling. These data indicate the feasibility of Ang II vaccine for preventing progression of vascular dementia.

27 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
CCChin Yang Chang
Chin Yang Chang
YKYu-Diao Kuan
Yu-Diao Kuan
JTJiayu A. Tai
Jiayu A. Tai
NJNAN JU
NAN JU
YLYen-Liang Li
Yen-Liang Li
MSMunehisa Shimamura
Munehisa Shimamura
Background/Objectives: Whole-cell vaccines have demonstrated clinical potential in cancer treatment and recurrence prevention, yet their immunogenicity and dendritic cell (DC) activation remain suboptimal. This study aimed to evaluate whether a needle-free injector (NFI) could enhance the immunogenicity and antitumor efficacy of whole-cell tumor vaccines. Methods: Adaptive immune responses induced by NFI and traditional syringe injection (SYI) were compared following whole-cell vaccine administration. The morphology of vaccine fluid ejected by NFI and SYI was examined, and the effects on DC antigen uptake and activation were assessed. Antitumor efficacy was further evaluated in MC38 colon adenocarcinoma challenge models. Results: NFI administration elicited stronger antigen-specific adaptive immune responses than SYI. The high-velocity pressure generated by NFI resulted in fragmentation of whole-cell vaccine material, and this morphological alteration was associated with enhanced DC antigen uptake and activation. These immunological improvements corresponded with superior tumor suppression in MC38 models following NFI-delivered vaccination. Conclusions: NFI delivery enhances the immunogenicity and antitumor efficacy of whole-cell tumor vaccines. These findings suggest that needle-free injectors may serve as a simple and effective strategy to improve the performance of whole-cell cancer vaccines.

17 June 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
NJNAN JU
NAN JU
CCChin Yang Chang
Chin Yang Chang
HHHiroki Hayashi
Hiroki Hayashi
STShuko Takeda
Shuko Takeda
TKTomohiro Kawano
Tomohiro Kawano
MSMunehisa Shimamura
Munehisa Shimamura
Low circulating levels of soluble fibroblast activation protein (sFAP) are associated with poor outcomes in patients with ischemic stroke, while its function in the ischemic brain remains unclear. This study investigated the role of FAP in ischemic stroke. BALB/c mice were subjected to transient middle cerebral artery occlusion and treated with recombinant FAP (rFAP) or CPD60, a selective FAP inhibitor. Temporal and spatial patterns of FAP expression in brain were analyzed. sFAP showed a greater decrease in CSF than in serum after ischemic stroke. Astrocytes expressed FAP but did not secrete it. Meningeal fibroblasts constitutively released FAP, and this release decreased after exposure to Toll-like receptor (TLR) 4 ligands. In cultured microglial and macrophages, rFAP suppressed TLR2/4-induced cytokine production. rFAP protected neurons and decreased tumor necrosis factor-α and interleukin-1β levels in neuron–glia cultures. Systemic or intracerebroventricular administration of rFAP reduced post-ischemic inflammation and infarct volume, whereas CPD60 worsened tissue injury. FAP also inhibited monocyte migration and inflammation induced by C-C motif chemokine ligand 2 and complement C1q tumor necrosis factor-related protein 6, suggesting that these chemokines are potential substrates. Overall, FAP regulates post-ischemic inflammation and protects neurons after ischemic stroke, indicating its therapeutic potential in ischemic stroke.